Myelodysplastic syndromes: biology and treatment

被引：39

作者：

Jadersten, M. ^{[1
]}

Hellstrom-Lindberg, E.

机构：

[1] Karolinska Univ Hosp, Dept Med, Karolinska Inst, Div Hematol, Stockholm, Sweden

来源：

JOURNAL OF INTERNAL MEDICINE | 2009年 / 265卷 / 03期

基金：

英国医学研究理事会;

关键词：

del(5q); EPO; G-CSF; prognosis; RPS14; SPARC; ACUTE MYELOID-LEUKEMIA; COLONY-STIMULATING FACTOR; QUALITY-OF-LIFE; RECOMBINANT-HUMAN-ERYTHROPOIETIN; COMMONLY DELETED REGION; CHRONIC MYELOMONOCYTIC LEUKEMIA; PROGNOSTIC SCORING SYSTEM; RIBOSOMAL-PROTEIN S19; RED-CELL APLASIA; TERM-FOLLOW-UP;

D O I：

10.1111/j.1365-2796.2008.02052.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Optimal management of patients with myelodysplastic syndromes (MDS) requires an insight into the biology of the disease and the mechanisms of action of the available therapies. This review focuses on low-risk MDS, for which chronic anaemia and eventual progression to acute myeloid leukaemia are the main concerns. We cover the updated World Health Organization classification, the latest prognostic scoring system, and describe novel findings in the pathogenesis of 5q- syndrome. We perform in depth analyses of two of the most widely used treatments, erythropoietin and lenalidomide, discussing mechanisms of action, reasons for treatment failure and influence on survival.

引用

页码：307 / 328

页数：22

共 203 条

[91] Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome [J].

Jadersten, Martin ;

Malcovati, Luca ;

Dybedal, Ingunn ;

Della Porta, Matteo Giovanni ;

Invernizzi, Rosangela ;

Montgomery, Scott M. ;

Pascutto, Cristiana ;

Porwit, Anna ;

Cazzola, Mario ;

Hellstrom-Lindberg, Eva .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (21) :3607-3613

[92]

Jaffe ES., 2001, WHO CLASSIFICATION T

[93]

Jaju RJ, 2000, GENE CHROMOSOME CANC, V29, P276, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1035>3.0.CO

[94]

2-L

[95]

JANSSEN JWG, 1989, BLOOD, V73, P248

[96] Molecular biology of erythropoietin [J].

Jelkmann, W .

INTERNAL MEDICINE, 2004, 43 (08) :649-659

[97] The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP [J].

Jelkmann, W .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2002, 69 (5-6) :265-274

[98] The fundamental role of epigenetic events in cancer [J].

Jones, PA ;

Baylin, SB .

NATURE REVIEWS GENETICS, 2002, 3 (06) :415-428

[99] Decitabine improves patient outcomes in myelodysplastic syndromes - Resuits of a Phase III randomized study [J].

Kantarjian, H ;

Issa, JPJ ;

Rosenfeld, CS ;

Bennett, JM ;

Albitar, M ;

DiPersio, J ;

Klimek, V ;

Slack, J ;

de Castro, C ;

Ravandi, F ;

Helmer, R ;

Shen, LL ;

Nimer, SD ;

Leavitt, R ;

Raza, A ;

Saba, H .

CANCER, 2006, 106 (08) :1794-1803

[100] Phase 1/2 study of AMG 531 in thrombocytopenic patients (pts) with low-risk Myelodysplastic syndrome (MDS): Update including extended treatment [J].

Kantarjian, Hagop ;

Fenaux, Pierre ;

Sekeres, Milckael A. ;

Becker, Pamela ;

Boruchov, Adam ;

Bowen, David ;

Larson, Richard ;

Lyons, Roger ;

Muus, Petra ;

Shammo, Jamile ;

Ehrman, Michael ;

Hu, Kuolung ;

Nichol, Janet .

BLOOD, 2007, 110 (11) :81A-81A

← 5 6 7 8 9 10 11 12 13 14 →